Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.

In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.

Among the highlights in this episode:

1:58 – The FDA begins cracking down on misinformation

2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs

3:06 – Doctors’ initial concerns about quality control

3:38 – Hesitancy about ‘transferability’

4:54 – Myth #2: Biosimilars won’t save money

5:50 – Myth #3: Biologics are natural monopolies

Contact Our Hosts:

Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org

Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org

We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org

Biosimilars were first introduced into the US market about six years ago, but getting the all-important &ldquo;patient buy-in&rdquo; has been a slow process. Many patients are reluctant to switch to a biosimilar if they&rsquo;re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.
In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.
Among the highlights in this episode:
1:58 &ndash; The FDA begins cracking down on misinformation
2:47 &ndash; Myth #1: Patients confuse biosimilar drugs with generic drugs
3:06 &ndash; Doctors&rsquo; initial concerns about quality control
3:38 &ndash; Hesitancy about &lsquo;transferability&rsquo;
4:54 &ndash; Myth #2: Biosimilars won&rsquo;t save money
5:50 &ndash; Myth #3: Biologics are natural monopolies
Contact Our Hosts:
Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF.&nbsp;<a href="mailto:zrothblatt@ghlf.org">zrothblatt@ghlf.org</a>
Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF.&nbsp;<a href="mailto:cmertens@ghlf.org">cmertens@ghlf.org</a>
We&rsquo;d love to hear what you think. Send your comments to&nbsp;<a href="mailto:BreakingDownBiosimilars@GHLF.org">BreakingDownBiosimilars@GHLF.org</a>

A podcast that sheds light on biosimilars and helps you better understand the role they play in your healthcare, now and in the future. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Zoe Rothblatt and Conner Mertens, both Patient Advocates and Community Outreach Managers at GHLF.

A podcast that sheds light on biosimilars and helps you better understand the role they play in your healthcare, now and in the future. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Zoe Rothblatt and Conner Mertens, both Patient Advocates and Community Outreach Managers at GHLF.

Breaking Down Biosimilars

A podcast that sheds light on biosimilars and helps you better understand the role they play in your healthcare- now and in the future. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Zoe Rothblatt and Conner Mertens, both Patient Advocates and Community Outreach Managers at GHLF.

A podcast that sheds light on biosimilars and helps you better understand the role they play in your healthcare- now and in the future. The podcast is part of the Global Healthy Living Foundation Podcast Network and hosted by Zoe Rothblatt and Conner Mertens, both Patient Advocates and Community Outreach Managers at GHLF.